MedTrace Logo

Myocardial Perfusion Assessment With Multidetector Computed Tomography

NCT00846079 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2009-02-18

No results posted yet for this study

Summary

Demonstrate the ability of muti-detector computed tomography to adequately perform stress testing will result in a veritable "one-stop shop" of non-invasive cardiac imaging that is, the ability to directly visualize heart arteries with high accuracy and to simultaniously determine the hemodynamic significance of any blockages visualized.

Conditions

Interventions

DEVICE

Regadenoson (Lexiscan) [muti-detector computed tomography]

Regadenason, typical dosing

Sponsors & Collaborators

  • General Electric

    collaborator INDUSTRY

  • Tennessee Heart and Vascular Institute, P.C.

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00846079 on ClinicalTrials.gov